Clinical trial
Real-world Comparative Effectiveness of Rivaroxaban Versus VKA
NCT02690155 is registered in ClinicalTrials.gov with Bayer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Real-world Comparative Effectiveness of Rivaroxaban Versus VKA
- Lead sponsor
- Bayer
- Phase
- Observational
- Overall status
- Completed
- Start date
- February 12, 2016
- Completion date
- March 1, 2016
- Enrollment
- 38,831 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.